Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Y-27632. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 known ✓ | O75116 | 8/20 | 1.00 |
| ▸ | ROCK1 known ✓ | Q13464 | 8/20 | 1.00 |
| ▸ | PRKCE known ✓ | Q02156 | 1/20 | 1.00 |
| ▸ | PRKD3 known ✓ | O94806 | 2/20 | 0.97 |
| ▸ | PRKCQ known ✓ | Q04759 | 2/20 | 0.97 |
| ▸ | PRKCD known ✓ | Q05655 | 2/20 | 0.97 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.97 |
| ▸ | GLA known ✓ | P06280 | 1/20 | 0.55 |
| ▸ | PRKCG known ✓ | P05129 | 1/20 | 0.54 |
| ▸ | PRKCI known ✓ | P41743 | 1/20 | 0.54 |
| ▸ | ACVR1 known ✓ | Q04771 | 1/20 | 0.54 |
| ▸ | ALK known ✓ | Q9UM73 | 1/20 | 0.54 |
| ▸ | PKN2 | Q16513 | 4/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | RPS6KA5 | O75582 | 3/20 | 0.97 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.97 |
| ▸ | CDK1 | P06493 | 2/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Y-27632 SCHEMBL819701 | 1.00 | ROCK2 (1.00) | ROCK2ROCK1PKN2TP53CYP3A4 | |
| Y-27632 SCHEMBL819702 | 1.00 | ROCK2 (1.00) | ROCK2ROCK1PKN2TP53CYP3A4 | |
| Y-27632 SCHEMBL1554110 | 1.00 | ROCK2 (1.00) | ROCK2ROCK1PKN2TP53CYP3A4 | |
| Y-27632 SCHEMBL30686996 | 1.00 | ROCK2 (1.00) | ROCK2ROCK1PKN2TP53CYP3A4 | |
| Y-27632 SCHEMBL1165652 | 1.00 | ROCK2 (1.00) | ROCK2ROCK1PKN2TP53CYP3A4 | |
| Y-27632 SCHEMBL2834049 | 1.00 | ROCK2 (1.00) | ROCK2ROCK1PKN2TP53CYP3A4 | |
| Y-27632 SCHEMBL364637 | 0.99 | ROCK2 (0.97) | ROCK2ROCK1PKN2TP53CYP3A4 | |
| Y-27632 SCHEMBL21954489 | 0.99 | ROCK2 (0.97) | ROCK2ROCK1PKN2TP53CYP3A4 | |
| Y-27632 SCHEMBL4296190 | 0.99 | ROCK2 (0.97) | ROCK2ROCK1PKN2TP53CYP3A4 | |
| Y-27632 SCHEMBL364638 | 0.99 | ROCK2 (0.97) | ROCK2ROCK1PKN2TP53CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112592896-B | Culture solution for lung adenocarcinoma organoid and culture method thereof | 深圳市第二人民医院(深圳市转化医学研究院) | 2024-06-25 | — | — | CN | claimed |
| CN-117285459-B | Preparation method of small molecule kinase inhibitor compound | 上海美迪西生物医药股份有限公司 | 2024-02-27 | — | — | CN | claimed |
| CN-117285459-A | Preparation method of small molecule kinase inhibitor compound | 上海美迪西生物医药股份有限公司 | 2023-12-26 | — | — | CN | claimed |
| EP-4703465-A1 | PLURIPOTENT STEM CELL-DERIVED RPE CELL, FORMULATION, PHARMACEUTICAL COMPOSITION, REAGENT, METHOD, AND KIT | Help Regenerative Medicine Technology (Shenzhen) Co., Ltd. (CN) | 2026-03-04 | — | — | EP | disclosed |
| US-12545898-B2 | Efficient and non-genetically modified iPSC-induced, industrialized single clone selection platform, and use | ALLIFE MEDICINE (ZHUHAI) LIMITED (CN) | 2026-02-10 | — | — | US | disclosed |
| US-20240191205-A1 | EFFICIENT AND NON-GENETICALLY MODIFIED IPSC-INDUCED, INDUSTRIALIZED SINGLE CLONE SELECTION PLATFORM, AND USE | ALLIFE MEDICINE (ZHUHAI) LIMITED (CN) | 2024-06-13 | — | — | US | disclosed |
| CN-117285459-B | Preparation method of small molecule kinase inhibitor compound | 上海美迪西生物医药股份有限公司 | 2024-02-27 | — | — | CN | disclosed |
| CN-117285459-A | Preparation method of small molecule kinase inhibitor compound | 上海美迪西生物医药股份有限公司 | 2023-12-26 | — | — | CN | disclosed |
| CN-113462638-B | Efficient genetic-modification-free iPSC induction and industrialization monoclonal picking platform and application | 呈诺再生医学科技(珠海横琴新区)有限公司 | 2022-10-25 | — | — | CN | disclosed |
| CN-112544613-B | Pluripotent stem cell cryopreservation liquid, application thereof and cryopreservation method | 武汉睿健医药科技有限公司 | 2022-08-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12545898-B2 | Efficient and non-genetically modified iPSC-induced, industrialized single clone selection platform, and use | SALL4, CD44, STING1 | ROCK2 2349/4885ROCK1 1611/4885PRKCE 2301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.